Trials / Unknown
UnknownNCT03412383
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- Peking Union Medical College · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | Pyrotinib 400mg/day |
Timeline
- Start date
- 2018-02-20
- Primary completion
- 2019-01-25
- Completion
- 2019-06-25
- First posted
- 2018-01-26
- Last updated
- 2018-01-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03412383. Inclusion in this directory is not an endorsement.